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Summary
Background A 2017 systematic review and meta-analysis of 55 prospective studies found the adjusted risk of HIV 
acquisition to be at least tripled in individuals with herpes simplex virus type 2 (HSV-2) infection. We aimed to assess 
the potential contribution of HSV-2 infection to HIV incidence, given an effect of HSV-2 on HIV acquisition.
Methods We used a classic epidemiological formula to estimate the global and regional (WHO regional) population 
attributable fraction (PAF) and number of incident HIV infections attributable to HSV-2 infection by age (15–24 years, 
25–49 years, and 15–49 years), sex, and timing of HSV-2 infection (established vs recently acquired). Estimates were 
calculated by incorporating HSV-2 and HIV infection data with pooled relative risk (RR) estimates for the effect of 
HSV-2 infection on HIV acquisition from a systematic review and meta-analysis. Because HSV-2 and HIV have 
shared sexual and other risk factors, in addition to HSV-related biological factors that increase HIV risk, we only used 
RR estimates that were adjusted for potential confounders.
Findings An estimated 420 000 (95% uncertainty interval 317 000–546 000; PAF 29·6% [22·9–37·1]) of 1·4 million 
sexually acquired incident HIV infections in individuals aged 15–49 years in 2016 were attributable to HSV-2 infection. 
The contribution of HSV-2 to HIV was largest for the WHO African region (PAF 37·1% [28·7–46·3]), women (34·8% 
[23·5–45·0]), individuals aged 25–49 years (32·4% [25·4–40·2]), and established HSV-2 infection (26·8% [19·7–34·5]).
Interpretation A large burden of HIV is likely to be attributable to HSV-2 infection, even if the effect of HSV-2 infection 
on HIV had been imperfectly measured in studies providing adjusted RR estimates, potentially because of residual 
confounding. The contribution is likely to be greatest in areas where HSV-2 is highly prevalent, particularly Africa. 
New preventive interventions against HSV-2 infection could not only improve the quality of life of millions of people 
by reducing the prevalence of herpetic genital ulcer disease, but could also have an additional, indirect effect on HIV 
transmission.
Funding WHO.
Copyright © 2019 World Health Organization; licensee Elsevier. This is an Open Access article published under the 
CC BY 3·0 IGO license which permits unrestricted use, distribution, and reproduction in any medium, provided 
the original work is properly cited. In any use of this article, there should be no suggestion that WHO endorses any 
specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved 
along with the article’s original URL.
Introduction
An estimated 417 million people globally had herpes 
simplex virus type 2 (HSV-2) infection in 2012,1 a lifelong 
infection that causes genital herpes.2 Prevalence of 
HSV-2 infection is highest in the WHO African region 
(32% vs 11% globally),1 which also has the highest HIV 
burden. According to UNAIDS estimates, in 2016, there 
were an estimated 25·4 million people living with HIV in 
the WHO African region, of a total of 36·3 million people 
living with HIV globally. Of the estimated 1·5 million 
incident HIV infections among individuals aged 
15–49 years in 2016, 950 000 (61%) were in the WHO 
African region. HSV-2 and HIV infections are closely 
associated; in the HIV Prevention Trials Network 
071 study in southern Africa, HIV prevalence was 41% in 
individuals with HSV-2 infection compared with 6% in 
those without HSV-2 infection.3
Evidence suggests there is a strong biological asso-
ciation between HIV and HSV-2 infections—specifically, 
that HSV-2 infection increases susceptibility to HIV 
acquisition, both viruses increase transmissibility of the 
other, and HSV-2 disease can become severe among 
people with HIV-related immunosuppression.4,5 The best 
characterised biological association (cofactor effect) 
between HSV-2 and HIV is the effect of HSV-2 infection 
on HIV acquisition. A 2017 systematic review and meta-
analysis of 55 prospective studies reported that the risk of 
HIV acquisition was almost tripled in the presence of 
For UNAIDS estimates see 
https://www.unaids.org/en/
resources/documents/ 
2017/20170720_Global_AIDS_
update_2017
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established (prevalent) HSV-2 infection and quintupled 
in the presence of recently acquired (incident) HSV-2 
infection.6 The biological plausibility for a cofactor effect 
of HSV-2 infection on HIV acquisition is compelling: 
ulcerative first episodes and recurrences of HSV-2 
infection result in disruption to the epithelial barrier, 
which facilitates the entry of HIV. The recruitment of 
immune cells to control initial HSV-2 infection and 
frequent reactivations (viral replication and shedding 
from the genital area) concentrates target cells for HIV in 
the genital area.4,5,7 Immune cells are recruited to the 
genital area regardless of whether viral reactivation is 
accompanied by symptoms,8 and this effect is seen even 
after 2 months of valaciclovir therapy.5,9 Biological data 
are consistent with the finding that HIV acquisition risk 
is higher for individuals recently infected with HSV-2 
than for those with established infection,6 as the first 
(symptomatic) episode of infection is longer in duration 
and more severe than subsequent recurrences10,11 and the 
number of days with recurrences and viral shedding 
(and thus with mucosal inflammation) is highest in the 
first year.5,12,13
A few studies have estimated the percentage of 
incident HIV infections that are attributable to HSV-2 
infection, known as the population attributable fraction 
(PAF).14–20 Existing estimates are, to our knowledge, only 
available for some settings in the WHO African 
region.15–20 Broader PAF estimation would enable a 
preliminary understanding of the potential global 
contribution of HSV-2 to HIV infection and how this 
contribution might differ across populations according 
to epidemic setting (ie, prevalence and incidence of 
HSV-2 and incidence of HIV). In this Article, we present 
the first global and regional (WHO regional) estimates 
of the PAF and number of incident HIV infections 
attributable to HSV-2 infection by age, sex, and timing 
of HSV-2 infection (established vs recently acquired). 
Estimates are provided for the general population and 
separately for female sex workers (FSWs) and men who 
have sex with men (MSM).
Methods
PAF formula and data sources
Our global and WHO regional (Americas, African, 
Eastern Mediterranean, European, South-East Asian, and 
Western Pacific) PAF estimates, were derived using the 
classic (Levin) epidemiological formula for polytomous 
exposure,14 which accounts for recently acquired and 
established HSV-2 infection:
Research in context
Evidence before this study
Biological and epidemiological evidence suggests that herpes 
simplex virus type 2 (HSV-2) infection increases the subsequent 
risk of acquiring HIV infection. A 2017 systematic review and 
meta-analysis of 55 prospective studies in which HSV-2 infection 
was known to precede HIV infection found the risk of HIV 
acquisition, adjusted for other shared risk factors for HIV and 
HSV-2 infections, to be almost tripled with established HSV-2 
infection (acquired >1 year ago) and quintupled in the presence 
of recently acquired HSV-2 infection (acquired within the past 
year). Although published estimates exist of the population 
attributable fraction (PAF) of incident HIV infection attributable 
to HSV-2 infection (as identified through a scoping review done 
for this study), they are available only for certain African settings. 
For the scoping review we searched PubMed from database 
inception to May, 2019, using search terms relating to HIV, 
HSV-2, and PAF.
Added value of this study
We combined the most recently available data on the burden of 
HSV-2 and HIV with pooled adjusted relative risk (RR) estimates 
for the effect of HSV-2 infection on HIV acquisition and used a 
classic epidemiological formula to translate these data into 
percentages and numbers of incident HIV infections 
attributable to HSV-2 infection in 2016. In so doing, 
we produced the first global and WHO-regional estimates of the 
potential contribution of HSV-2 infection to the HIV epidemic. 
These estimates are needed for improving our understanding 
of the extent to which HSV-2 infection contributes to HIV 
infections and how this varies across populations, which in 
turn informs where future intervention efforts would be best 
targeted to have maximum impact.
Implications of all the available evidence
HSV-2 infection is an important risk factor for HIV acquisition, 
and people with known HSV-2 infection could benefit from 
heightened HIV prevention efforts. We used only adjusted RR 
estimates in our PAF calculations to most closely reflect 
biological rather than behavioural risk. Although residual 
confounding could still have been present, our findings suggest 
that the contribution of HSV-2 infection to HIV acquisition is 
substantial given the high prevalence of HSV-2 infection 
globally, even if the effect of HSV-2 infection on HIV 
transmission is not necessarily measured perfectly in the 
available studies. Interventions targeted against HSV-2, 
such as new vaccines or microbicides, have the potential to 
improve the lives of millions of people by reducing recurrent 
genital herpetic symptoms. In addition, in the presence of 
an effect of HSV-2 infection on HIV acquisition, prevention 
measures against HSV-2 transmission could have a further, 
indirect benefit on HIV.
PAF (%) =
[1 + PHSV-2_established × (RRHSV-2_established – 1) 
+ PHSV-2_recent × (RRHSV-2_recent – 1)] 
[PHSV-2_established × (RRHSV-2_established – 1) 
+ PHSV-2_recent × (RRHSV-2_recent – 1)] × 100% 
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where PHSV-2_established is the proportion of individuals with 
established HSV-2 infection in the overall population 
(ie, individuals infected and uninfected with HSV-2), 
PHSV-2_recent is the proportion of individuals with recently 
acquired HSV-2 infection in the overall population (ie, 
individuals infected and uninfected with HSV-2), 
RRHSV-2_established is the relative risk (RR) of HIV acquisition 
among individuals with established HSV-2 infection versus 
those without HSV-2 infection, and RRHSV-2_recent is the RR of 
HIV acquisition among individuals with recently acquired 
HSV-2 infection versus those without HSV-2 infection.
Recently acquired HSV-2 infection was defined as 
infection acquired within the past year and established 
HSV-2 infection as an HSV-2 infection acquired more 
than 1 year ago.
Once the PAF has been calculated, it can then be applied 
to the total number of incident HIV infections from sexual 
transmission in a given population for a given year to 
obtain the number of incident HIV infections attributable 
to HSV-2 infection in that population for that year.
Data on the RR of HIV acquisition, occurrence of 
established or recently acquired HSV-2 infection, and HIV 
incidence to inform parameter values in the PAF formula 
were taken from the most recent literature reviews1,6 or 
were official UNAIDS estimates available at the time of 
analysis, as specified in detail in the next paragraphs. Data 
sources for the parameters had slightly varying time 
frames but were applied to 2016 UNAIDS HIV incidence 
estimates to estimate the number of incident HIV in-
fections in 2016 that were attributable to HSV-2 infection.
We extracted pooled RR estimates for the effect of HSV-2 
infection on HIV acquisition (combining hazard ratios, 
rate ratios, and odds ratios across prospective studies) and 
95% CIs from our 2017 systematic review and meta-
analysis of 55 prospective studies from literature searched 
between Jan 1, 2003, and May 25, 2017, and from studies 
published before 2003 identified in a 2006 systematic 
review.6,21 To minimise confounding from shared risk 
factors for HIV and HSV-2 infections and any mutual 
effect of HIV infection on HSV-2 acquisition, RR estimates 
were based on studies that adjusted for shared risk factors 
and in which HSV-2 infection was known to have preceded 
HIV acquisition. Table 1 summarises estimates and 
number of studies available by sex, risk population 
(general population, MSM, FSWs, and other high-risk 
groups), and time since HSV-2 infection (recently acquired 
or established).6 All studies included in the meta-analysis 
for the general population, and all but one study of FSWs, 
were from Africa, whereas all studies of MSM were from 
outside Africa (mostly the USA, but also Australia, China, 
Thailand, and the Caribbean). Only one study reported RR 
estimates for the effect of recently acquired HSV-2 
infection on HIV acquisition in men.
Estimates of the proportion of individuals with 
established HSV-2 infection (with 95% uncertainty 
intervals [UIs]) or recently acquired HSV-2 infection 
(without 95% UIs) for the general population, stratified 
by age (in 5-year age bands from age 15 years to 49 years), 
sex, and WHO region, were available from the 2012 WHO 
estimates for prevalent and incident HSV-2 infection, 
which were informed by a comprehensive literature 
review up to February, 2014, that included 111 studies.1 
For those estimates, incidence was derived by calib rating 
the force of infection (incidence per susceptible in-
dividual) to prevalence, assuming a constant force of 
infection by age.22 Prevalence was calculated for each year 
of age, and the force of infection was applied to the 
number of susceptible individuals at that age to estimate 
the number of new infections over 1 accumulated year 
of age.
In addition, we combined age-stratified data from 
44 studies of HSV-2 prevalence among MSM and FSWs 
(excluding those with HIV) with year of data collection 
2000 or later and a sample size of 20 or greater. These data 
were collated during the same literature review but not 
used in the 2012 WHO estimates (appendix 1).1 After 
adjusting for assay performance, we weighted the data by 
sample size using a random-effects model to derive pooled 
estimates of the proportion of MSM or FSWs with 
established HSV-2 infection by WHO region. As HSV-2 
prevalence data among MSM were not available for the 
African and Eastern Mediterranean regions, we estimated 
the proportion of MSM with established HSV-2 infection 
in these regions by multiplying the proportion of men in 
the general populations in those regions with established 
HSV-2 infection by the global (ie, all other WHO regions) 
mean ratio of established HSV-2 infection in MSM to 
established HSV-2 infection in the general male 
population. For example, for African MSM:
where r denotes region (r=1 for the Americas, r=2 for 
European, r=3 for South-East Asian, r=4 for Western 
Pacific, r=5 for African, and r=6 for Eastern Mediterranean) 
and k denotes sex (k=0 for women and k=1 for men). We 
calculated the global mean ratio of established HSV-2 
infection in MSM to established HSV-2 infection in the 
general male population,
to be 2·8.
We used UNAIDS estimates of the annual number 
of incident HIV infections by WHO region, age 
(a; 15–24 years, 25–49 years, and 15–49 years), and sex for 
2016 (NHIV_r,a,k). Not all estimates had 95% UIs so we 
derived them when necessary on the basis of the size of 
available uncertainty bounds for other estimates (as a 
PHSV-2_established_r = 5,MSM = 
PHSV-2_established_r,MSM[( PHSV-2_established_r,k = 1
(
/ 4
[
× PHSV-2_established_r = 5,k = 1 
∑
r = 4
r = 1
PHSV-2_established_r,MSM[( PHSV-2_established_r,k = 1
(
/ 4
[∑r = 4
r = 1
See Online for appendix 1
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proportion of the estimate). In addition, we used 
UNAIDS estimates of the distribution (relative 
proportion, X) of all incident HIV infections by key 
population (MSM, FSWs, people who inject drugs 
[PWID], transgender individuals, sexual partners of 
high-risk individuals, and other [all remaining 
individuals]) that were calculated by WHO region for 
2015.23 We used X to estimate the number of incident 
HIV infections occurring in FSWs (NHIV_r,FSW), MSM 
(NHIV_r,MSM), and PWID (NHIV_r,PWID) in each region, 
assuming for PWID equal proportions in women and 
men and that all HIV transmissions were through 
contaminated equipment:
The number of incident infections among PWID was 
then used to estimate the number of incident 
HIV infections due to sexual transmission alone: 
NHIV_r,a,k_sexual = NHIV_r,a,k – NHIV_r,a,k_PWID. The PAF of incident 
HIV attributable to HSV-2 infection was calculated both 
for incident HIV infection from sexual transmission only 
(since HSV-2-associated HIV infection is sexually 
acquired) and for all incident HIV infections (with HIV 
infections in PWID being unaffected by HSV-2). The 
PAF for all incident HIV infections was calculated by 
multiplying the PAF for incident HIV infections from 
sexual transmission only by NHIV_r,a,k_sexual/NHIV_r,a,k.
PAF estimation
We derived global and regional (WHO regional) estimates 
of the PAF and number of incident HIV infections 
attributable to HSV-2 infection for the general population 
by age (15–24 years, 25–49 years, and 15–49 years), sex, and 
timing of HSV-2 infection, and separately for MSM and 
FSWs. The age range 15–49 years and two age groups 
within this range were chosen because HSV-2 infection 
and HIV incidence estimates were available for individuals 
aged 15–49 years and for the age groups 15–24 years and 
25–49 years. The age range 15–49 years also reflects peak 
exposure to HSV-2 and HIV. All available estimates and 
assumptions made to derive the PAF are summarised in 
appendix 2 (pp 6–8).
We used RR estimates in the general population 
by sex in the PAF calculations for women, men, and 
women and men combined. We used the RR for the 
effect of recently acquired HSV-2 infection on HIV 
acquisition in men and women combined in the PAF 
formula for men because only one study informed the 
RR for the effect in men (table 1). We used specific RR 
estimates for MSM and FSWs in the PAF calculations for 
these two key population groups. We did not estimate the 
PAF for the contribution of recently acquired HSV-2 
infection to HIV incidence in MSM and FSWs given the 
scarcity of data to inform the proportion of individuals 
with recently acquired HSV-2 infection.
The global number of incident HIV infections 
attributable to HSV-2 infection was obtained by summing 
the numbers for all WHO regions. Global PAF estimates 
were then derived from the total number of incident HIV 
infections attributable to HSV-2 infection.
We derived 95% UIs of PAF estimates and estimates 
of the number of incident HIV infections attributable to 
HSV-2 infection using a Monte Carlo sampling method 
to sample the proportion of individuals with established 
NHIV_r,a,k × Xr,FSW NHIV_r,FSW  = 
a,k
∑
   NHIV_r,a,k × Xr,MSM NHIV_r,MSM  =∑
a,k
NHIV_r,a,k, PWID  = NHIV_r,a,k × Xr,PWID
Established HSV-2 infection Recently acquired HSV-2 infection
Number of studies 
informing RR estimate
Pooled adjusted RR 
(95% CI)
I² Number of studies 
informing RR estimate
Pooled adjusted RR 
(95% CI)
I²
General population* 22 2·7 (2·2–3·4) 59% 6 4·7 (2·2–10·1) 64%
Women only 11 2·5 (1·8–3·4) 68% 5 7·2 (4·5–11·5) 0%
Men only 10 3·1 (2·2–4·3) 48% 1 1·1 (0·4–3·1)† ··
Both sexes 1 8·7 (1·1–67·2) ·· ·· ·· ··
Men who have sex with men† 7 1·7 (1·4–2·1) 26% 1 2·8 (0·8–9·9)† ··
Female sex workers‡ 7 1·5 (0·8–2·7) 65% 1 3·0 (1·6–5·3)† ··
Other high-risk groups 
(women, men, or both)§¶
11 Pooling not done|| ·· ·· ·· ··
HSV=herpes simplex virus. RR=relative risk. *All studies were in Africa. †Four studies informing the RR estimate for established HSV-2 infection were in the Americas, one in 
South-East Asia, one in Western Pacific, and one in more than one WHO region; the one study informing the RR estimate for recently acquired HSV-2 infection was in the 
Americas. ‡Six studies informing the RR estimate for established HSV-2 infection were in Africa and one was in South-East Asia; the one study informing the RR estimate for 
recently acquired HSV-2 infection was in Africa. §High-risk populations were female workers in bars, hotels, and food and recreational facilities; serodiscordant couples; male 
trucking-company employees; male military conscripts; attendees of sexually transmitted infection clinics; and women reported as being at high risk. ¶Six studies informing 
the RR estimate for established HSV-2 infection were in the Americas, four were in South-East Asia, and one was in Western Pacific. ||Range of individual-study estimates was 
0·5 (95% CI 0·2–1·1) to 4·3 (1·5–12·4).
Table 1: Studies informing pooled, adjusted RR estimates of HIV acquisition attributable to HSV-2 infection by time since HSV-2 infection, risk 
population, and sex6
See Online for appendix 2
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HSV-2 infection, RR estimates, and HIV incidence 
(PHSV-2_established, RRHSV-2_established, RRHSV-2_recent, NHIV) within 
plausible ranges. We ran the Monte Carlo sampling 
1000 times in Microsoft Excel 2003 (and above). 
PHSV-2_established was sampled in two steps: first, sampling on 
the log-odds scale from a normal distribution, with the 
mean equal to the log-odds of infection and the SD equal 
to the SE of the log-odds of infection, and then back-
transforming from the log-odds scale to a probability to 
use in the PAF calculations. RRHSV-2_established and RRHSV-2_recent 
were sampled using the same two steps as for PHSV-2_established 
but on the log scale rather than the log-odds scale. NHIV 
was sampled from a normal distribution with the mean 
equal to the number of infections and the SD equal to 
the SE of the number of infections, but sampled values 
were truncated at zero. We did not sample the proportion 
of individuals with recently-acquired HSV-2 infection, 
since 95% UIs were unavailable.1 The 95% UI was 
based on the 2·5 and 97·5 percentiles from the set of 
1000 generated estimates.
All calculations were done with Microsoft Excel. 
A completed GATHER checklist is given in appendix 2 (p 5).
Role of the funding source
The funder of the study had no role in study design, data 
collation, data analysis, data interpretation, or writing 
of the report. However, SLG, affiliated with WHO, 
commissioned the study, contributed to the direction of 
the work, and edited and commented on the drafts. The 
corresponding author had full access to all the data in the 
study and had final responsibility for the decision to 
submit for publication.
Results
We estimated that the global PAF of incident HIV infection 
from sexual transmission in 2016 that was attributable to 
HSV-2 infection was 29·6% (95% UI 22·9–37·1). The PAF 
was highest for the WHO African region (37·1%, 95% UI 
28·7–46·3) and the Americas (21·3%, 14·7–29·4), and was 
11–13% elsewhere in the world (figure; table 2).
Of the estimated 1·4 million incident HIV infections 
from sexual transmission among individuals aged 
15–49 years globally in 2016, we estimated that 420 000 
(95% UI 317 000–546 000) were attributable to HSV-2 
infection (table 2). Most incident HIV infections 
attributable to HSV-2 infection were in the WHO African 
region (figure; table 2).
The PAF and number of incident HIV infections 
attributable to HSV-2 infection in individuals aged 
15–49 years were higher among women than men 
(table 3), reflecting the higher proportion of women than 
men with HSV-2 infection and the higher RR for women 
than for men for the effect of recently acquired HSV-2 
infection on HIV acquisition (table 1).6 For women and 
Figure: Estimated number and PAF of incident HIV infections among individuals aged 15–49 years in 2016 that were attributable to HSV-2 infection, by 
WHO region
Data are n (95% UI) or % (95% UI). Number of incident HIV infections attributable to HSV-2 infection is given to the nearest thousand. 95% UIs were generated 
through separate sampling for each WHO region and globally; therefore, regional lower and upper bounds do not sum to the global bounds. PAF=population 
attributable fraction. UI=uncertainty interval.
African region
Region of the Americas
South-East Asia region
European region
Eastern Mediterranean region
Western Pacific region
30 000
(20 000–42 000);
PAF 21·3% (14·7–29·4)
346 000
(253 000–454 000);
PAF 37·1% (28·7–46·3)
15 000
(9000–24 000);
PAF 11·6% (7·0–19·4)
2000
(1000–4000);
PAF 12·3% (7·5–20·1)
10 000
(2000–22 000);
PAF 13·0% (6·5–23·7)
15 000
(7000–29 000);
PAF 12·4% (6·2–22·1)
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men combined, the PAF was higher for individuals aged 
25–49 years than for those aged 15–24 years (table 3). 
Similar patterns by age and sex were seen by region 
(appendix 2 pp 9, 10).
We estimated that 20 000 (0–44 000) incident HIV 
infections in FSWs and 40 000 (17 000–62 000) incident 
HIV infections in MSM in 2016 were attributable to 
established HSV-2 infection (table 3).
The PAF of incident HIV infection attributable to 
recently acquired HSV-2 infection was consistently low 
across regions (less than 4%; table 2), but it had a larger 
contribution among younger age groups and women 
(table 3).
The PAF of incident HIV infection acquired from all 
transmission routes attributable to HSV-2 infection was 
similar to that of incident HIV infection attributable to 
HSV-2 infection acquired from sexual transmission only 
(table 3). The exception was for regions where a substantial 
proportion of HIV infections are acquired in PWID, 
notably the Eastern Mediterranean (33 000 incident 
PAF of incident HIV infections from sexual transmission 
attributable to HSV-2 infection
Number of incident HIV 
infections attributable to
all HSV-2 infections*
Number of incident 
HIV infections from 
sexual transmission*†
All HSV-2 infections Established HSV-2 
infections
Recently acquired 
HSV-2 infections
General population
Women
15–24 years 30·8% (22·3–40·2) 21·4% (11·8–31·7) 9·4% (5·2–15·6) 105 000 (61 000–156 000) 340 000
25–49 years 36·4% (24·7–46·9) 33·7% (21·1–44·8) 2·7% (1·5–4·8) 127 000 (76 000–182 000) 348 000
15–49 years 34·8% (23·5–45·0) 29·6% (17·2–40·6) 5·1% (2·8–8·9) 239 000 (140 000–357 000) 689 000
Men
15–24 years 17·9% (11·0–27·1) 14·6% (8·1–23·6) 3·3% (0·9–7·5) 41 000 (20 000–72 000) 231 000
25–49 years 30·2% (19·6–40·9) 28·4% (17·7–39·2) 1·8% (0·5–4·1) 148 000 (76 000–245 000) 492 000
15–49 years 26·2% (16·9–37·3) 23·9% (14·6–34·7) 2·3% (0·7–5·3) 189 000 (99 000–314 000) 723 000
Women and men combined
15–24 years 23·2% (16·8–31·0) 18·6% (12·8–25·4) 4·6% (1·7–10·1) 133 000 (94 000–181 000) 572 000
25–49 years 32·4% (25·4–40·2) 30·6% (23·3–38·5) 1·8% (0·7–4·1) 272 000 (207 000–347 000) 840 000
Key risk populations‡
Female sex workers 26·7% (0·0–56·5) 26·7% (0·0–56·5) ·· 20 000 (0–44 000)§ 77 000
Men who have sex with men 19·9% (8·7–28·7) 19·9% (8·7–28·7) ·· 40 000 (17 000–62 000)§ 203 000
Data are % (95% UI), n (95% UI), or n. The number of incident HIV infections attributable to HSV-2 infection was calculated for each age and sex group separately; therefore, 
estimates do not sum exactly across rows. PAF=population attributable fraction. UI=uncertainty interval. *Estimates are shown to the nearest thousand; they are based on 
2016 HIV incidence data, 2012 HSV-2 infection estimates,1 key population HSV-2 prevalence data reviewed as part of the 2012 work on HSV-2 infection estimates,1 RR 
estimates from a review of literature published up until 2017,6 and key population breakdown of HIV incidence for 2015.23 †Denominators for calculation of PAFs. ‡Only 
established HSV-2 infections were considered, and not recently acquired ones. §These numbers form a subset of the global numbers and are not in addition to them.
Table 3: Estimated global PAF and number of incident HIV infections in 2016 attributable to HSV-2 infection, by age, sex, and risk population
PAF of incident HIV infection attributable to HSV-2 infection Number of incident HIV 
infections attributable to 
all HSV-2 infections†
Number of incident 
HIV infections from 
sexual transmission†‡
Number of incident 
HIV infections from 
all routes of HIV 
transmission†§
All HSV-2 infections Established HSV-2 
infections
Recently acquired 
HSV-2 infections
All incident HIV 
infection*
African 37·1% (28·7–46·3) 33·7% (24·8–43·1) 3·4% (1·3–7·5) 36·4% (28·1–45·4) 346 000 (253 000–454 000) 932 000 951 000
Americas 21·3% (14·7–29·4) 19·2% (12·4–27·5) 2·1% (0·8–4·6) 20·5% (14·1–28·2) 30 000 (20 000–42 000) 140 000 146 000
Eastern Mediterranean 12·3% (7·5–20·1) 11·5% (6·6–19·5) 0·8% (0·3–1·9) 5·9% (3·6–9·7) 2000 (1000–4000) 16 000 33 000
European 11·6% (7·0–19·4) 10·6% (5·9–18·3) 1·0% (0·4–2·2) 7·4% (4·5–12·4) 15 000 (9000–24 000) 126 000 198 000
South-East Asian 12·4% (6·2–22·1) 11·2% (5·1–21·2) 1·2% (0·4–2·6) 11·5% (5·8–20·5) 15 000 (7000–29 000) 124 000 134 000
Western Pacific 13·0% (6·5–23·7) 11·8% (5·2–22·5) 1·2% (0·4–2·6) 11·0% (5·5–20·1) 10 000 (2000–22 000) 74 000 87 000
Global average (all regions) 29·6% (22·9–37·1) 26·8% (19·7–34·5) 2·7% (1·0–6·0) 27·0% (20·8–33·9) 420 000 (317 000–546 000) 1 411 000 1 548 000
Data are % (95% UI), n (95% UI), or n. PAF=population attributable fraction. UI=uncertainty interval. *Includes incident HIV infections from all routes of transmission (not just sexual transmission). †Estimates are 
shown to the nearest thousand; they are based on 2016 HIV incidence data, 2012 HSV-2 infection estimates,1 RR estimates from a review of literature published up until 2017,6 and key population breakdown of 
HIV incidence for 2015.23 ‡Denominators for calculation of PAFs of incident HIV infection via sexual transmission attributable to HSV-2 infection. §Denominators for calculation of PAFs of incident HIV infection 
via all routes of transmission attributable to HSV-2 infection.
Table 2: Estimated PAF and number of incident HIV infections in 2016 attributable to HSV-2 infection among individuals aged 15–49 years, overall and by WHO region
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infections from all routes of transmission vs 16 000 incident 
infections from sexual transmission) and European 
regions (198 000 vs 126 000).23
Discussion
We estimated that 420 000 (95% UI 317 000–546 000; PAF 
29·6%, 95% UI 22·9–37·1) of 1·4 million incident HIV 
infections acquired via sexual transmission in individuals 
aged 15–49 years in 2016 were attributable to HSV-2 
infection. However, this global figure masks large 
regional differences: by far the largest number and 
proportion of incident HIV infections attributable to 
HSV-2 infection were in Africa. This finding reflects the 
larger burden of HSV-2 and HIV infections in this region 
than elsewhere. The estimated PAF was highest for 
women and individuals aged 25–49 years because of a 
greater proportion of people in these populations having 
HSV-2 infection.1 It was also higher for established than 
recently acquired HSV-2 infection, despite the higher 
RR for recently acquired than for established HSV-2 
infection (table 1); this finding can be explained by many 
more people having established than recently acquired 
HSV-2 infection, especially at older ages. The PAF was 
estimated to be lower for FSWs and MSM than for the 
general population because of lower RR estimates for 
these key risk populations.
To our knowledge, we report the first global and 
regional estimates of the PAF and number of incident 
HIV infections attributable to HSV-2 infection. These 
estimates are useful for understanding the potential 
magnitude of the contribution of HSV-2 infection to 
HIV, which can help stimulate development of new 
interventions and guide where future prevention efforts 
would be best targeted for optimal effect. Our PAF 
estimates were based on the most recent WHO estimates 
of HSV-2 prevalence and incidence among general 
populations (informed by 111 studies), and HSV-2 
prevalence estimates for FSWs and MSM (based on 
44 studies) were from a global review.1 The estimates were 
also based on RR estimates of the effect of HSV-2 
infection on HIV acquisition from a 2017 systematic 
review and meta-analysis6 of 55 prospective studies and 
the most recently available UNAIDS estimates of HIV 
incidence and breakdown by key populations.23 However, 
the PAF estimates have some limitations. First, the same 
limitations and caveats affecting the estimates of HSV-2 
infection1 and HIV infection23 apply here, such as the 
availability and generalisability of contributing studies. 
The HSV-2 prevalence and incidence estimates used in 
our PAF calculations were based on 2012 population data. 
However, they used prevalence data published up to 
2014 and overall prevalence changes slowly since HSV-2 
is a life-long infection. We were also limited by the number 
and types of studies contributing data to the RR estimates, 
which did not allow use of age-specific, sex-specific, 
and region-specific RR estimates in all calculations 
and required us to make additional assumptions.6 For 
example, we applied the RR for recently acquired HSV-2 
infection among women and men combined to calculate 
PAF estimates for men in the general population because 
only one estimate was available for men. Similarly, we did 
not use RR estimates stratified by age or WHO region 
because of the small number of studies that were 
available. In the systematic review,6 there was some 
evidence that, for recently acquired HSV-2 infection, 
RR estimates were higher for younger individuals 
than older ones. However a univariate meta-regression 
analysis (combining RR estimates for established and 
recently acquired HSV-2 infection) did not find a 
significant association for age on RR estimates.6 In the 
systematic review,6 it was not possible to separate the 
effects of region and risk group because there were no 
RR estimates for general populations outside of Africa. 
However, RR estimates for established HSV-2 infection, 
which contributed more to HIV incidence than recently 
acquired infection, were the best informed by data and 
suggested similar estimates among men and women and 
by age. RR estimates might be different for general 
populations outside of Africa but without any data it is 
difficult to speculate on this possibility.
The issues about underlying data availability and 
assumptions were partly mitigated by calculating UIs. 
We were unable to account for uncertainty in the pro-
portion of individuals with recently acquired HSV-2 
infection, which might, in principle, have led to under-
estimation of uncertainty in the PAF estimates. However, 
this underestimation is unlikely because, as noted above, 
individuals with recently acquired HSV-2 infection are a 
minority and as a result contributed little to the PAF 
estimates.
A second limitation of the PAF estimates is that, by 
definition, they assume a causal link—in this case, an 
association between HSV-2 and HIV that is not solely a 
reflection of confounding.24 Even with the most rigorously 
collected and analysed observational data, it is difficult 
to completely disentangle the biological cofactor effect 
from other dynamics (eg, confounding). In deriving the 
RR estimates applied here,6 only adjusted estimates were 
pooled, the majority of which were adjusted for sexual 
behaviour. In addition, adjustment was found not to 
markedly affect the magnitude of the RR estimates, and 
RR estimates were also remarkably consistent across 
studies.6 Furthermore, we restricted our estimates of HIV 
acquisition attributable to recently acquired HSV-2 
infection to RRs from studies with known timing of 
HSV-2 infection in relation to HIV. We found that recently 
acquired HSV-2 infection had a stronger cofactor effect 
on HIV acquisition than established HSV-2 infection,6 
which could favour a biological explanation since a first 
episode of HSV-2 infection is more severe than 
subsequent recurrences.10,12,25 However, finding of an 
association between HSV-2 infection and HIV acquisition 
and biological plausibility do not eliminate the possibility 
of residual confounding of the observed association 
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between HSV-2 and HIV infections, especially in relation 
to sexual network and partner characteristics.24,26–28 Our 
estimates, therefore, reflect the contribution of HSV-2 
infection to incident HIV infection only to the extent that 
the adjusted RRs accurately depict the magnitude of the 
effect of HSV-2 on HIV acquisition. Nonetheless, these 
estimates provide a starting point in understanding 
the potential contribution of HSV-2 infection to HIV 
acquisition globally, given the available data.
Finally, HSV-2 seems to have an additional cofactor 
effect on HIV transmissibility (ie, the biological asso-
ciation of HSV-2 infection on increasing HIV infec-
tiousness),4 which was not included in our calculations 
and could increase the PAF of HIV acquisition 
attributable to HSV-2.29 Another consideration is that the 
classic PAF formula does not take into account the effect 
of HSV-2 infection on onward, secondary transmission 
of HIV.30 Because our PAF estimates were calculated for 
a single year (2016), we might have underestimated the 
contribution of HSV-2 infection to HIV acquisition over 
time. This work could be extended further with 
mathematical modelling of HSV-2 and HIV transmission 
at the population level to estimate how secondary 
infections resulting from the cofactor effect of HSV-2 
infection on HIV acquisition further contribute to the 
PAF and to explore how changing epidemiology over 
time is reflected in the PAF. Mathematical modelling 
could also be used to explore the association between 
HIV and HSV-2 for more than one cofactor effect 
simultaneously.
Previously published PAF estimates15–20 from some 
settings in Africa, which were derived using either the 
classic PAF formula14 or a statistical model (which uses a 
classic formula), varied according to the age and sex of 
the population for which the PAF was being estimated 
and the RR found by the study.15–20 In a study in Mwanza 
(Tanzania), the PAF for HIV acquisition attributable to 
HSV-2 infection was calculated to be 59% using a 
statistical model, of which 46% was due to established 
HSV-2 infection and 13% to recently acquired HSV-2 
infection.15 The PAF was found to be higher among men 
than women, with the lowest PAF found among women 
aged 15–24 years (12%, 95% CI –46 to 47) and the highest 
among men aged 25–54 years (76%, 43 to 90), although 
confidence intervals around these estimates were very 
wide.16 A slightly higher PAF, also obtained using a 
statistical model, was found for women (67%, 52–78) 
than for men (61%, 40–74) in a study in southwestern 
Uganda, with the PAF varying over time with the 
prevalence of HSV-2 infection.17 In a study in high-risk 
women in Mombasa (Kenya), the PAF was found to be 
48% for established HSV-2 infection and 5% for recently 
acquired HSV-2 infection using a PAF formula based on 
HSV-2 status among incident HIV cases,14 but also in this 
case the PAF varied with the prevalence of HSV-2 
infection over time.18 Using this same formula, the PAF 
was estimated to be 29% for established HSV-2 infection 
versus 2% for recently acquired HSV-2 infection 
among women in Harare (Zimbabwe), Durban, and 
Johannesburg (South Africa),19 and 50% for established 
infection versus 8% for recently acquired infection 
among women in Uganda and Zimbabwe.20
These estimates highlight the important link between 
HSV-2 and HIV infections and suggest that the global 
contribution of HSV-2 infection to HIV acquisition could 
be substantial. The link between HSV-2 and HIV 
infections has implications for both the management of 
people with known HSV-2 infection and for HSV-2 and 
HIV prevention efforts. For example, in settings or 
populations with high HIV incidence, individuals with 
symptoms suggestive of HSV-2 infection could benefit 
from HIV testing and more focused HIV prevention 
efforts, such as pre-exposure prophylaxis.31
New interventions against HSV-2, such as vaccines, 
new antivirals, or microbicides, have the potential to 
substantially reduce genital ulcer disease, which affects 
millions of people worldwide.1,32,33 In addition, our PAF 
estimates suggest that interventions directed against 
HSV-2 could also have an indirect effect on HIV 
incidence. This effect would enhance the public health 
value of HSV-2 prevention interventions. Even con-
sidering the uncertainty inherent in our analysis and in 
the absolute magnitude of the effect of HSV-2 infection 
on HIV acquisition, the fact that there were 1·5 million 
new HIV infections among individuals aged 15–49 years 
in 2016 and more than 400 million HSV-2 infections 
means that an indirect effect of HSV-2 prevention on 
HIV has the potential to prevent hundreds of thousands 
of HIV infections annually. In Africa, where HSV-2 
prevalence is high in the heterosexual population, use of 
an effective intervention against HSV-2 would have the 
greatest potential effect on both HIV and HSV-2 
infections. The effect would be less pronounced in 
regions such as the Eastern Mediterranean and Europe, 
where a higher proportion of HIV infections are related 
to injection drug use than in other regions.
Trials of daily suppressive antiviral therapy against 
HSV-2 did not show a reduction in HIV acquisition; 
however, it has been speculated that the antivirals 
evaluated did not sufficiently reduce the HSV-associated 
influx of immune cell targets for HIV for there to be an 
effect on HIV acquisition.5,8,34 Antivirals do not fully 
suppress viral shedding, leading to immune cell per-
sistence,9,35 and bioavailability of, and adherence to, 
aciclovir in the suppressive therapy trials were also cited 
as potential issues.34,36,37 New, more effective interventions 
could hold more promise for translating an effect on 
HSV-2 infection or shedding and disease into gains for 
the reduction of HIV incidence.33
The landscape for HIV prevention and treatment has 
transformed in the past decade, with expanded availability 
of HIV prevention interventions such as antiretroviral 
treatment, pre-exposure prophylaxis, and voluntary 
medi cal male circumcision.38 However, no intervention 
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used alone is likely to be sufficient to achieve global goals 
to end the HIV epidemic, especially given challenges in 
uptake and adherence. Hence, combination measures 
are needed.39 A potential indirect effect of interventions 
against HSV-2 on HIV incidence will need to be evaluated 
in the context of existing HIV prevention interventions 
and for new interventions against HSV-2, particularly 
HSV-2 vaccines.33 Our estimates suggest that HSV-2 
prevention measures could be an important additional 
tool in the fight against HIV.
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